The apparent adverse impact of elevated FGF23 on non-cardiovascular risk conceivably could reflect, at least in part, the ability of FGF23 to act as a growth factor for certain cancers, including possibly prostate cancer [33,34,35,36,37]. Here, FGF23 is linked to prostate carcinoma.